Suppr超能文献

肿瘤衰老:来自小鼠和人类的证据。

Senescence in tumours: evidence from mice and humans.

机构信息

Spanish National Cancer Research Centre, Madrid, Spain.

出版信息

Nat Rev Cancer. 2010 Jan;10(1):51-7. doi: 10.1038/nrc2772.

Abstract

The importance of cellular senescence, which is a stress response that stably blocks proliferation, is increasingly being recognized. Senescence is prevalent in pre-malignant tumours, and progression to malignancy requires evading senescence. Malignant tumours, however, may still undergo senescence owing to interventions that restore tumour suppressor function or inactivate oncogenes. Senescent tumour cells can be cleared by immune cells, which may result in efficient tumour regression. Standard chemotherapy also has the potential to induce senescence, which may partly underlie its therapeutic activity. Although these concepts are well supported in mouse models, translating them to clinical oncology remains a challenge.

摘要

细胞衰老作为一种稳定阻止增殖的应激反应,其重要性正日益受到重视。衰老普遍存在于恶性前期肿瘤中,而向恶性肿瘤的进展则需要逃避衰老。然而,由于恢复肿瘤抑制功能或失活癌基因的干预,恶性肿瘤仍可能发生衰老。衰老的肿瘤细胞可以被免疫细胞清除,这可能导致肿瘤的有效消退。标准的化疗也有可能诱导衰老,这可能是其治疗活性的部分基础。尽管这些概念在小鼠模型中得到了很好的支持,但将其转化为临床肿瘤学仍然是一个挑战。

相似文献

1
Senescence in tumours: evidence from mice and humans.
Nat Rev Cancer. 2010 Jan;10(1):51-7. doi: 10.1038/nrc2772.
2
Cellular senescence in the development and treatment of cancer.
Curr Pharm Des. 2010 Jan;16(1):79-100. doi: 10.2174/138161210789941874.
3
Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines.
Int J Oncol. 2018 Nov;53(5):1997-2009. doi: 10.3892/ijo.2018.4553. Epub 2018 Sep 5.
5
T-helper-1-cell cytokines drive cancer into senescence.
Nature. 2013 Feb 21;494(7437):361-5. doi: 10.1038/nature11824. Epub 2013 Feb 3.
6
Senescent vascular endothelial cells promote oral squamous cell carcinoma progression through complement C3 activation.
Arch Oral Biol. 2025 Jun;174:106242. doi: 10.1016/j.archoralbio.2025.106242. Epub 2025 Mar 23.
7
[Senescence and cellular immortality].
Bull Cancer. 2010 Nov;97(11):1275-83. doi: 10.1684/bdc.2010.1205.
8
The power and the promise of oncogene-induced senescence markers.
Nat Rev Cancer. 2006 Jun;6(6):472-6. doi: 10.1038/nrc1884.
9
The impact of cellular senescence in cancer therapy: is it true or not?
Acta Pharmacol Sin. 2011 Oct;32(10):1199-207. doi: 10.1038/aps.2011.108. Epub 2011 Sep 12.

引用本文的文献

1
Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression.
J Exp Clin Cancer Res. 2025 Aug 14;44(1):236. doi: 10.1186/s13046-025-03501-9.
2
Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis.
J Med Chem. 2025 Aug 14;68(15):15683-15694. doi: 10.1021/acs.jmedchem.5c00537. Epub 2025 Jul 30.
3
Molecular "Yin-Yang" Machinery of Synthesis of the Second and Third Fullerene C Derivatives.
Micromachines (Basel). 2025 Jun 30;16(7):770. doi: 10.3390/mi16070770.
4
The Molecular Interplay Between p53-Mediated Ferroptosis and Non-Coding RNAs in Cancer.
Int J Mol Sci. 2025 Jul 9;26(14):6588. doi: 10.3390/ijms26146588.
5
Clinical and molecular characterizations of HNSCC patients with occult lymph node metastasis.
Sci Rep. 2025 Jul 12;15(1):25263. doi: 10.1038/s41598-025-10320-7.
6
Immunometabolism and oxidative stress: roles and therapeutic strategies in cancer and aging.
NPJ Aging. 2025 Jul 1;11(1):59. doi: 10.1038/s41514-025-00250-z.
7
Future Perspectives in Senescence-Based Therapies for Head and Neck Cancer.
Cancers (Basel). 2025 Jun 12;17(12):1965. doi: 10.3390/cancers17121965.
8
KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma.
Transl Oncol. 2025 Jul;57:102421. doi: 10.1016/j.tranon.2025.102421. Epub 2025 May 17.
9
Extracellular Vesicles in the Aging Male Reproductive System: Progresses and Perspectives.
Adv Exp Med Biol. 2025;1469:375-394. doi: 10.1007/978-3-031-82990-1_16.

本文引用的文献

1
Awakening guardian angels: drugging the p53 pathway.
Nat Rev Cancer. 2009 Dec;9(12):862-73. doi: 10.1038/nrc2763.
2
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.
Nat Cell Biol. 2009 Sep;11(9):1135-42. doi: 10.1038/ncb1928. Epub 2009 Aug 23.
3
Real-time in vivo imaging of p16Ink4a reveals cross talk with p53.
J Cell Biol. 2009 Aug 10;186(3):393-407. doi: 10.1083/jcb.200904105.
4
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7979-84. doi: 10.1073/pnas.0900343106. Epub 2009 Apr 29.
5
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Oncogene. 2009 Jun 11;28(23):2289-98. doi: 10.1038/onc.2009.95. Epub 2009 Apr 27.
6
Oncogenic Braf induces melanocyte senescence and melanoma in mice.
Cancer Cell. 2009 Apr 7;15(4):294-303. doi: 10.1016/j.ccr.2009.02.022.
8
Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells.
Dis Model Mech. 2009 Jan-Feb;2(1-2):56-67. doi: 10.1242/dmm.001016. Epub 2008 Dec 22.
10
Modelling Myc inhibition as a cancer therapy.
Nature. 2008 Oct 2;455(7213):679-83. doi: 10.1038/nature07260. Epub 2008 Aug 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验